The Zurex technology platform consists of a proprietary and novel antimicrobial formulation originally designed to prevent healthcare acquired infections in hospitals and healthcare settings. PharmAgra applies the same technology platform to the agricultural animal and veterinary markets. The ZuraLac product is a novel, non-iodine based sanitizer targeting dairy mastitis. ZuraLac has been University tested, demonstrated significant efficacy against common dairy mastitis causing organisms, with and without organic load, and shown superior teat end conditioning in cold weather conditions when compared to standard iodine based products. The formulation also provides a unique “visual indicator” of antimicrobial activity for the dairy producer.
“We are very excited about the launch of the ZuraLac family of teat treatments,” said Mike Pawlak, Director of Agricultural Operations. “The novel formulation, broad spectrum kill against mastitis causing organisms, safe and gentle-to-skin formulation and visual indicator of activity provide a valuable new product to the industry.”
PharmAgra also announced that Nicholas C. Babson was recently appointed to serve on its Board of Directors. Mr. Babson is currently President of NCB Ventures LLC. The majority of his career was spent with Babson Bros. Co., formerly a global manufacturer and distributor of dairy equipment and supplies, where he held a number of positions including Chairman of the Board and Chief Executive Officer. “The strategic initiatives underway at PharmAgra are poised to meet the demands of a rapidly changing landscape in agriculture. This could be a real ‘game changer’ for the industry,” said Mr. Babson.
“Zurex PharmAgra is very pleased to welcome Nick to our Board of Directors as his knowledge and experience in agriculture are legendary. Everyone in the business knows that the name ‘Babson’ is synonymous with World Class agricultural leadership,” said Carmine J. Durham, Chief Executive Officer of PharmAgra.